The role of latency reversal in HIV cure strategies

One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune-mediated cell death. This is called latency reversal. Despite clear activity of multiple latency reversal agents in vitro, clinical trials of latency-reversing agents have not shown significant reduction in latently infected cells. We review new insights into the biology of HIV latency and discuss novel approaches to enhance the efficacy of latency reversal agents.

Automated summary

Although multiple latency reversal agents have shown activity in vitro, clinical trials have not demonstrated significant reduction in latently infected cells. New insights into the biology of HIV latency are being reviewed and novel approaches to enhance the efficacy of latency reversal agents are being discussed.